Tejas Savant
Stock Analyst at Morgan Stanley
(2.37)
# 2,581
Out of 5,148 analysts
251
Total ratings
43.26%
Success rate
-0.72%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GRAL GRAIL | Maintains: Equal-Weight | $110 → $60 | $52.63 | +14.00% | 4 | Feb 24, 2026 | |
| VCYT Veracyte | Maintains: Underweight | $40 → $48 | $36.01 | +33.30% | 15 | Dec 2, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $508.58 | +31.74% | 16 | Dec 2, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $80 → $85 | $53.31 | +59.44% | 6 | Dec 2, 2025 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $24 | $15.09 | +59.05% | 3 | Dec 2, 2025 | |
| PSNL Personalis | Maintains: Equal-Weight | $9 → $11 | $9.06 | +21.41% | 14 | Dec 2, 2025 | |
| NTRA Natera | Maintains: Overweight | $220 → $265 | $200.17 | +32.39% | 15 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $174.27 | +52.06% | 12 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $23.14 | -13.57% | 16 | Dec 2, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $69 → $76 | $75.45 | +0.73% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $16 | $16.12 | -0.74% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $132.89 | -20.99% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $8.81 | +36.21% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $9.50 | -15.79% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $4.43 | +58.01% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $8.21 | -14.74% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.61 | +38.50% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $5.01 | +319.16% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.62 | +23.46% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $7.05 | +467.38% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.32 | +158.62% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.62 | +116.45% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $4.40 | -37.50% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.73 | +478.03% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $92.23 | -20.85% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $178.61 | +39.97% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $15.75 | +534.92% | 5 | May 12, 2022 |
GRAIL
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $110 → $60
Current: $52.63
Upside: +14.00%
Veracyte
Dec 2, 2025
Maintains: Underweight
Price Target: $40 → $48
Current: $36.01
Upside: +33.30%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $508.58
Upside: +31.74%
Tempus AI
Dec 2, 2025
Maintains: Overweight
Price Target: $80 → $85
Current: $53.31
Upside: +59.44%
Stevanato Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $24
Current: $15.09
Upside: +59.05%
Personalis
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $11
Current: $9.06
Upside: +21.41%
Natera
Dec 2, 2025
Maintains: Overweight
Price Target: $220 → $265
Current: $200.17
Upside: +32.39%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $174.27
Upside: +52.06%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $23.14
Upside: -13.57%
Hologic
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $69 → $76
Current: $75.45
Upside: +0.73%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $16.12
Upside: -0.74%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $132.89
Upside: -20.99%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $8.81
Upside: +36.21%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $9.50
Upside: -15.79%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $4.43
Upside: +58.01%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $8.21
Upside: -14.74%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.61
Upside: +38.50%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $5.01
Upside: +319.16%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.62
Upside: +23.46%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $7.05
Upside: +467.38%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.32
Upside: +158.62%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.62
Upside: +116.45%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $4.40
Upside: -37.50%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.73
Upside: +478.03%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $92.23
Upside: -20.85%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $178.61
Upside: +39.97%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $15.75
Upside: +534.92%